CN106581063B - 一种用于增强记忆力的血浆分离物及其制备方法和应用 - Google Patents
一种用于增强记忆力的血浆分离物及其制备方法和应用 Download PDFInfo
- Publication number
- CN106581063B CN106581063B CN201611247899.2A CN201611247899A CN106581063B CN 106581063 B CN106581063 B CN 106581063B CN 201611247899 A CN201611247899 A CN 201611247899A CN 106581063 B CN106581063 B CN 106581063B
- Authority
- CN
- China
- Prior art keywords
- blood plasma
- concentration
- product
- isolate
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002381 plasma Anatomy 0.000 title claims abstract description 194
- 230000015654 memory Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 54
- 238000000502 dialysis Methods 0.000 claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- HIVLDXAAFGCOFU-UHFFFAOYSA-N ammonium hydrosulfide Chemical compound [NH4+].[SH-] HIVLDXAAFGCOFU-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000002708 enhancing effect Effects 0.000 claims abstract description 28
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 27
- 238000005349 anion exchange Methods 0.000 claims abstract description 21
- 238000001556 precipitation Methods 0.000 claims abstract description 15
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 14
- 230000002779 inactivation Effects 0.000 claims abstract description 12
- 150000003384 small molecules Chemical class 0.000 claims abstract description 11
- 239000000047 product Substances 0.000 claims description 103
- 239000007853 buffer solution Substances 0.000 claims description 35
- 238000010828 elution Methods 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 239000000872 buffer Substances 0.000 claims description 30
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000003480 eluent Substances 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- 150000001450 anions Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 13
- 230000000937 inactivator Effects 0.000 claims description 13
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 12
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 12
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 11
- 239000003405 delayed action preparation Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- 239000012149 elution buffer Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 238000004925 denaturation Methods 0.000 claims description 7
- 230000036425 denaturation Effects 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000001502 gel electrophoresis Methods 0.000 claims description 5
- -1 microballoon Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 238000001228 spectrum Methods 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 102100034613 Annexin A2 Human genes 0.000 claims 4
- 108090000668 Annexin A2 Proteins 0.000 claims 4
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 2
- 108010028777 Complement C8 Proteins 0.000 claims 2
- 102000016916 Complement C8 Human genes 0.000 claims 2
- 102000001399 Kallikrein Human genes 0.000 claims 2
- 108060005987 Kallikrein Proteins 0.000 claims 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 108090000104 Actin-related protein 3 Proteins 0.000 claims 1
- 102100027211 Albumin Human genes 0.000 claims 1
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 claims 1
- 101710125089 Bindin Proteins 0.000 claims 1
- 102000004958 Caspase-14 Human genes 0.000 claims 1
- 108090001132 Caspase-14 Proteins 0.000 claims 1
- 108010075016 Ceruloplasmin Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 102100030556 Coagulation factor XII Human genes 0.000 claims 1
- 108010028776 Complement C7 Proteins 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 108090000044 Complement Factor I Proteins 0.000 claims 1
- 102100024336 Complement component C7 Human genes 0.000 claims 1
- 102100035431 Complement factor I Human genes 0.000 claims 1
- 102100036871 Cyclin-J Human genes 0.000 claims 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims 1
- 101710096438 DNA-binding protein Proteins 0.000 claims 1
- 102000004860 Dipeptidases Human genes 0.000 claims 1
- 108090001081 Dipeptidases Proteins 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 101710120810 Elongation factor 1-alpha 1 Proteins 0.000 claims 1
- 102000006402 Endocrine-Gland-Derived Vascular Endothelial Growth Factor Human genes 0.000 claims 1
- 108010044063 Endocrine-Gland-Derived Vascular Endothelial Growth Factor Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000001653 FEMA 3120 Substances 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 102000004878 Gelsolin Human genes 0.000 claims 1
- 108090001064 Gelsolin Proteins 0.000 claims 1
- 102100038073 General transcription factor II-I Human genes 0.000 claims 1
- 101710144827 General transcription factor II-I Proteins 0.000 claims 1
- 102100030386 Granzyme A Human genes 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 101000779572 Homo sapiens Alpha-protein kinase 3 Proteins 0.000 claims 1
- 101000713131 Homo sapiens Cyclin-J Proteins 0.000 claims 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 1
- 101000956887 Homo sapiens Immunoglobulin lambda variable 2-8 Proteins 0.000 claims 1
- 101000836337 Homo sapiens Probable helicase senataxin Proteins 0.000 claims 1
- 101000788412 Homo sapiens Probable methyltransferase TARBP1 Proteins 0.000 claims 1
- 101000842302 Homo sapiens Protein-cysteine N-palmitoyltransferase HHAT Proteins 0.000 claims 1
- 101710146024 Horcolin Proteins 0.000 claims 1
- 102100038428 Immunoglobulin lambda variable 2-8 Human genes 0.000 claims 1
- 108010076371 Lumican Proteins 0.000 claims 1
- 102000011681 Lumican Human genes 0.000 claims 1
- 108010085169 Lysine carboxypeptidase Proteins 0.000 claims 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 claims 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 claims 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 claims 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 claims 1
- 101000782223 Mus musculus Brorin Proteins 0.000 claims 1
- 102100028762 Neuropilin-1 Human genes 0.000 claims 1
- 108090000772 Neuropilin-1 Proteins 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 claims 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 claims 1
- 101710132772 Peroxidase 1 Proteins 0.000 claims 1
- 101001005349 Photobacterium leiognathi Long-chain acyl-protein thioester reductase 1 Proteins 0.000 claims 1
- 102100027178 Probable helicase senataxin Human genes 0.000 claims 1
- 102100025214 Probable methyltransferase TARBP1 Human genes 0.000 claims 1
- 102100030616 Protein-cysteine N-palmitoyltransferase HHAT Human genes 0.000 claims 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 claims 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 claims 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 claims 1
- 102000014034 Transcortin Human genes 0.000 claims 1
- 108010011095 Transcortin Proteins 0.000 claims 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims 1
- 244000295923 Yucca aloifolia Species 0.000 claims 1
- 235000004552 Yucca aloifolia Nutrition 0.000 claims 1
- 235000012044 Yucca brevifolia Nutrition 0.000 claims 1
- 235000017049 Yucca glauca Nutrition 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 108060003196 globin Proteins 0.000 claims 1
- 102000018146 globin Human genes 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 230000014621 translational initiation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 57
- 230000000971 hippocampal effect Effects 0.000 description 47
- 230000000694 effects Effects 0.000 description 44
- 238000000034 method Methods 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 230000000946 synaptic effect Effects 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 230000002572 peristaltic effect Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000003292 glue Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 238000011818 5xFAD mouse Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000011017 operating method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000001977 collision-induced dissociation tandem mass spectrometry Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000003138 coordinated effect Effects 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- ZJHHPAUQMCHPRB-UHFFFAOYSA-N urea urea Chemical compound NC(N)=O.NC(N)=O ZJHHPAUQMCHPRB-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611247899.2A CN106581063B (zh) | 2016-12-29 | 2016-12-29 | 一种用于增强记忆力的血浆分离物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611247899.2A CN106581063B (zh) | 2016-12-29 | 2016-12-29 | 一种用于增强记忆力的血浆分离物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106581063A CN106581063A (zh) | 2017-04-26 |
CN106581063B true CN106581063B (zh) | 2018-11-06 |
Family
ID=58605187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611247899.2A Active CN106581063B (zh) | 2016-12-29 | 2016-12-29 | 一种用于增强记忆力的血浆分离物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106581063B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1569031A (zh) * | 2004-04-26 | 2005-01-26 | 巫山 | 病毒灭活/超滤膜分段筛分法制备的血浆组分系列制剂 |
CN101232893A (zh) * | 2005-08-11 | 2008-07-30 | 株式会社美迪基尼斯 | 包含血浆或血清的用于治疗神经损伤的药物成分 |
CN102250240A (zh) * | 2011-06-27 | 2011-11-23 | 山东泰邦生物制品有限公司 | 一种从血浆分离组分ⅰ+ⅲ中纯化人免疫球蛋白的方法 |
CN103910790B (zh) * | 2014-03-28 | 2016-06-29 | 贵州泰邦生物制品有限公司 | 一种制备人血浆蛋白c浓缩物的方法 |
CN106074600A (zh) * | 2016-06-24 | 2016-11-09 | 田野 | 自血浆中分离出的用于增强记忆力的混合物及其制备方法和应用 |
CN106138097A (zh) * | 2016-06-24 | 2016-11-23 | 田野 | 从血浆中分离用于治疗阿尔兹海默症的混合物的方法及混合物和应用 |
CN106163530A (zh) * | 2013-12-09 | 2016-11-23 | 小利兰·斯坦福大学托管委员会 | 用于治疗衰老相关病症的方法和组合物 |
-
2016
- 2016-12-29 CN CN201611247899.2A patent/CN106581063B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1569031A (zh) * | 2004-04-26 | 2005-01-26 | 巫山 | 病毒灭活/超滤膜分段筛分法制备的血浆组分系列制剂 |
CN101232893A (zh) * | 2005-08-11 | 2008-07-30 | 株式会社美迪基尼斯 | 包含血浆或血清的用于治疗神经损伤的药物成分 |
CN102250240A (zh) * | 2011-06-27 | 2011-11-23 | 山东泰邦生物制品有限公司 | 一种从血浆分离组分ⅰ+ⅲ中纯化人免疫球蛋白的方法 |
CN106163530A (zh) * | 2013-12-09 | 2016-11-23 | 小利兰·斯坦福大学托管委员会 | 用于治疗衰老相关病症的方法和组合物 |
CN103910790B (zh) * | 2014-03-28 | 2016-06-29 | 贵州泰邦生物制品有限公司 | 一种制备人血浆蛋白c浓缩物的方法 |
CN106074600A (zh) * | 2016-06-24 | 2016-11-09 | 田野 | 自血浆中分离出的用于增强记忆力的混合物及其制备方法和应用 |
CN106138097A (zh) * | 2016-06-24 | 2016-11-23 | 田野 | 从血浆中分离用于治疗阿尔兹海默症的混合物的方法及混合物和应用 |
Non-Patent Citations (2)
Title |
---|
Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020proteins and a publicly-available database;Gilbert S. Omenn, et al.;《Proteomics》;20051231(第5期);第3226-3245页 * |
血浆蛋白组学技术及其应用进展;张海洋等;《中国微循环》;20090630;第13卷(第3期);第207-210页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106581063A (zh) | 2017-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106074600B (zh) | 自血浆中分离出的用于增强记忆力的混合物及其制备方法和应用 | |
US20080299212A1 (en) | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum | |
CN106138097B (zh) | 从血浆中分离用于治疗阿尔兹海默症的混合物的方法及混合物和应用 | |
CN102088862A (zh) | 血管生成素富集的乳级分 | |
EP1597271B1 (de) | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung | |
CN107709350A (zh) | 纯化和/或病毒灭活的方法 | |
JPS62174027A (ja) | 改良されたキモパパイン及び製薬学的組成物 | |
CN106581063B (zh) | 一种用于增强记忆力的血浆分离物及其制备方法和应用 | |
CN106890192B (zh) | 一种增强记忆的源自血浆的混合物及其制备方法和应用 | |
CN106511378B (zh) | 一种用于增强记忆力的血浆提取物及其制备方法和应用 | |
CN106692192B (zh) | 一种提高记忆的从血浆分离的混合物及其制备方法和应用 | |
CN106581062B (zh) | 一种用于改善记忆力的混合物及其制备方法和应用 | |
CN113801219A (zh) | 一种转铁蛋白的制备方法及包含转铁蛋白的组合物和应用 | |
US20220380439A1 (en) | Purification of fviii from plasma using silicon oxide adsorption | |
CN110787187B (zh) | 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用 | |
CN103408625A (zh) | 一种纯化dna的方法 | |
CN110724176B (zh) | 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用 | |
CN105586330B (zh) | 一种尖吻蝮蛇凝血酶及其制备方法 | |
JPH07155194A (ja) | タンパク質の精製法 | |
RU2799637C1 (ru) | Способ получения биологически активного пептидно-аминокислотного препарата на основе плазмы крови человека | |
JPH0665060A (ja) | 治療薬を送達するための親水性クリーム | |
US6372510B1 (en) | Method for removing unconventional transmissible agents from a protein solution | |
JPH0453848B2 (zh) | ||
Grellet et al. | An associated process for the purification of immuno globulin g, catalase, superoxide dismutase and albumin from haemolysed human placenta blood | |
US20230029456A1 (en) | Method of purifying botufinum toxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Lin Inventor after: Cui Wenhong Inventor after: Xuan Chunling Inventor after: Zhang Lili Inventor after: Kong Yirong Inventor after: Hao Jingyu Inventor after: Shi Haowei Inventor before: Cui Wenhong Inventor before: Zhang Lili Inventor before: Kong Yirong Inventor before: Hao Jingyu Inventor before: Shi Haowei Inventor before: Ren Yuanyuan |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180409 Address after: 100094 1, 115, 117, 123, 125 rooms, 1 building, 538 Yongfeng Tun, Haidian District, Beijing. Applicant after: Beijing HAOSI Biotechnology Co. Ltd. Address before: 100000 Beijing city Haidian District renjishanzhuang D502 Applicant before: Tian Ye |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 102208 room 102-2, 1f, building 1, courtyard 7, kekekeyuan Road, Huilongguan town, Changping District, Beijing Patentee after: Beijing HAOSI Biotechnology Co.,Ltd. Address before: 100094 1, 115, 117, 123, 125 rooms, 1 building, 538 Yongfeng Tun, Haidian District, Beijing. Patentee before: Beijing HAOSI Biotechnology Co.,Ltd. |